Promising new treatment strategy for type 2 diabetes

The FDA is con­tin­u­ing to low­er the bar of its ap­proval stan­dards for nov­el drug ap­pli­ca­tions, ac­cord­ing to a new analy­sis of ev­i­dence on ap­provals

The FDA on Wednes­day ap­proved Basilea’s an­tibi­ot­ic Zevtera to treat three con­di­tions: staph in­fec­tions, acute bac­te­r­i­al skin and skin struc­ture in­fec­tions, and com­mu­ni­ty-ac­quired bac­te­r­i­al pneu­mo­nia.